Type 2 diabetes is a metabolic disorder characterized by insulin resistance as well as a
progressive deterioration of pancreatic β-cell mass and function. Glucagon-like peptide 1 …

Abstract Glucagon-like peptide-1 (GLP-1), an incretin hormone, is released from intestinal L-
cells in response to nutrients. GLP-1 lowers blood glucose levels by stimulating insulin …

Glucagon-like peptide 1 (GLP-1) is an intestine-derived insulinotropic hormone that
stimulates glucose-dependent insulin production and secretion from pancreatic β-cells …

Glucagon-like peptide-1 (GLP-1)-based therapy of type 2 diabetes is executed either by GLP-
1 receptor agonists, which stimulate the GLP-1 receptors, or by dipeptidyl peptidase-4 (DPP …

Glucagon-like peptide-1 (GLP-1) circulates at low levels and acts as an incretin hormone,
potentiating glucose-dependent insulin secretion from islet β cells. GLP-1 also modulates …

Abstract Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone that, when given
exogenously, is capable of normalizing blood glucose in individuals with type 2 diabetes …

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from enteroendocrine L
cells in response to ingested nutrients. The first recognized and most important action of …

Objective Glucagon-like peptide 1 (GLP-1) enhances insulin secretion and protects β-cell
mass. Diabetes therapies targeting the GLP-1 receptor (GLP-1R), expressed in numerous …

Type 2 diabetes occurs when the β-cells do not secrete enough insulin to counter balance
insulin resistance. GLP-1 and GIP are insulinotropic peptides which are thought to benefit to …

The first antidiabetic treatment (exenatide; Byetta) based on the incretin hormone glucagon-
like peptide-1 (GLP-1) was approved in 2005 as an adjunctive therapy in diabetic patients in …